These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 18624857)

  • 1. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo.
    Sanclemente G; Garcia JJ; Zuleta JJ; Diehl C; Correa C; Falabella R
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1359-64. PubMed ID: 18624857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.
    Kumaran MS; Kaur I; Kumar B
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):269-73. PubMed ID: 16503885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
    Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
    Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
    Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
    Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo.
    Rodríguez-Martín M; García Bustínduy M; Sáez Rodríguez M; Noda Cabrera A
    Br J Dermatol; 2009 Feb; 160(2):409-14. PubMed ID: 19016706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
    Bakis-Petsoglou S; Le Guay JL; Wittal R
    Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo.
    van Geel N; Ongenae K; De Mil M; Haeghen YV; Vervaet C; Naeyaert JM
    Arch Dermatol; 2004 Oct; 140(10):1203-8. PubMed ID: 15492182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.
    Westerhof W; Nieuweboer-Krobotova L
    Arch Dermatol; 1997 Dec; 133(12):1525-8. PubMed ID: 9420536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo.
    Schallreuter KU; Krüger C; Würfel BA; Panske A; Wood JM
    Int J Dermatol; 2008 Jul; 47(7):743-53. PubMed ID: 18613887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
    Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
    Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of vitiligo with narrow-band UVB and topical gel containing catalase and superoxide dismutase.
    Kostović K; Pastar Z; Pasić A; Ceović R
    Acta Dermatovenerol Croat; 2007; 15(1):10-4. PubMed ID: 17433173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients.
    Hofer A; Hassan AS; Legat FJ; Kerl H; Wolf P
    Br J Dermatol; 2005 May; 152(5):981-5. PubMed ID: 15888156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
    Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
    J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
    Dell'Anna ML; Mastrofrancesco A; Sala R; Venturini M; Ottaviani M; Vidolin AP; Leone G; Calzavara PG; Westerhof W; Picardo M
    Clin Exp Dermatol; 2007 Nov; 32(6):631-6. PubMed ID: 17953631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical trial of clobetasol propionate in Filipino vitiligo patients.
    Geraldez CB; Gutierrez GT
    Clin Ther; 1987; 9(5):474-82. PubMed ID: 3311364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
    Middelkamp-Hup MA; Bos JD; Rius-Diaz F; Gonzalez S; Westerhof W
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):942-50. PubMed ID: 17659004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical immunomodulators are effective for treatment of vitiligo.
    Choi CW; Chang SE; Bak H; Choi JH; Park HS; Huh CH; Kim CW; Kim SE; Mun SK; Kim BJ; Kim MN
    J Dermatol; 2008 Aug; 35(8):503-7. PubMed ID: 18789070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo.
    Newman MD; Silverberg NB
    Cutis; 2011 Nov; 88(5):256-9. PubMed ID: 22272490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.